- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.08. | OSR Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 27.08. | Emerging Growth Research Issues Company-Sponsored Research Flash Report on OSR Health, Inc. | 587 | ACCESS Newswire | NEW YORK CITY, NY / ACCESS Newswire / August 27, 2026 / Emerging Growth Research, LLC ("Emerging Growth Research" or "EGR") today announced the release of its company-sponsored research flash report... ► Artikel lesen | |
| 21.08. | OSR Health, Inc.: OSR Health: Preparing Our Appeal, Advancing Our Catalysts, Continuing Our Mission | 562 | ACCESS Newswire | The Company details its Nasdaq hearing request, its $15 million Put Option, and continued development across its subsidiary pipeline BELLEVUE, WA / ACCESS Newswire / August 21, 2026 / OSR Health, Inc.... ► Artikel lesen | |
| 19.08. | OSR Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| OSR HEALTH Aktie jetzt für 0€ handeln | |||||
| 19.08. | OSR Health faces Nasdaq delisting over bid-price rule | 1 | Seeking Alpha | ||
| 19.08. | OSR Health droht NASDAQ-Delisting nach Verstoß gegen Mindestkurs-Anforderung | 1 | Investing.com Deutsch | ||
| 19.08. | Nasdaq to delist OSR Health after bid price compliance failure | 1 | Investing.com | ||
| 19.08. | OSR Health, Inc.: OSR Health Receives Nasdaq Staff Delisting Determination and Intends to Request Hearings Panel Appeal | 1.270 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that it has received a written Staff Delisting Determination (the "Determination")... ► Artikel lesen | |
| 19.08. | OSR Health, Inc.: OSR Health Sees Global Shareholder Momentum at Critical Inflection Point | 667 | ACCESS Newswire | Company cites extraordinary trading activity, global shareholder support, and continued commitment to Nasdaq compliance and the CVR program. BELLEVUE, WA / ACCESS Newswire / August 19, 2026 / OSR Health... ► Artikel lesen | |
| 14.08. | OSR Health, Inc. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 11.08. | Drohendes NASDAQ-Delisting: OSR Health verweist auf Lizenzgespräche | 19 | Investing.com Deutsch | ||
| 11.08. | OSR Health, Inc.: OSR Health CEO Reaffirms Confidence and Highlights Subsidiary Business Development | 730 | ACCESS Newswire | Founder and CEO addresses the Company's Nasdaq listing status and accelerating subsidiary business development BELLEVUE, WA / ACCESS Newswire / August 11, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today... ► Artikel lesen | |
| 10.08. | OSR Health: Aktionäre bestätigen Vorstand und genehmigen wichtige Anträge auf Hauptversammlung | 7 | Investing.com Deutsch | ||
| 07.08. | OSR Health, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 07.08. | OSR Health, Inc.: OSR Health Issues Clarification Regarding Prior Nasdaq Communication and Shareholder Loyalty CVR Program | 524 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / August 7, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today issued a clarification regarding its press release dated July 31, 2026 concerning... ► Artikel lesen | |
| 03.08. | OSR Health subsidiary completes glioblastoma vaccine analysis | 4 | Investing.com | ||
| 03.08. | OSR Health, Inc.: Vaximm AG, an OSR Company, Announces Forthcoming Publication of Cross-Indication Clinical Data for VXM01, Its VEGFR-2-Targeted Cancer Vaccine Platform | 289 | ACCESS Newswire | Encouraging data from two glioblastoma studies are expected to be submitted for publication in the coming months BELLEVUE, WA / ACCESS Newswire / August 3, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today... ► Artikel lesen | |
| 31.07. | OSR Health, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 31.07. | OSR Health, Inc.: OSR Health Secures Nasdaq Communication: Loyalty CVR Program Will Not Trigger a Price Adjustment | 545 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / July 31, 2026 / OSR Health, Inc. (NASDAQ:OSRH) ("OSR Health" or the "Company") today announced that the Nasdaq Stock Market ("Nasdaq") stated in a verbal communication... ► Artikel lesen | |
| 13.07. | OSR Health, Inc.: OSR Health, A Message From the CEO | 605 | ACCESS Newswire | BELLEVUE, WA / ACCESS Newswire / July 13, 2026 / OSR Health, Inc. (NASDAQ:OSRH) today released the following letter from Chief Executive Officer to shareholders.To Every OSR Health Shareholder:OSR Health... ► Artikel lesen |
1 2 3 Weiter >>
58 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -2,05 % | PacBio Announces Second Quarter 2026 Financial Results | MENLO PARK, Calif., Aug. 05, 2026 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended June 30, 2026. Recent Business Highlights Total revenue of $39.0... ► Artikel lesen | |
| CYTOMX THERAPEUTICS | 2,856 | +0,49 % | CytomX auf Wells-Fargo-Konferenz: Fokus auf EpCAM-Wirkstoff und solide Liquidität | ||
| CARISMA THERAPEUTICS INC | 0,028 | 0,00 % | United Immunity Acquires Macrophage Assets from Carisma Therapeutics | ||
| CAPRICOR | 7,442 | +3,05 % | Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Lead Plaintiff Deadline on September 28, 2026 | ||
| CORMEDIX | 7,162 | +6,14 % | CorMedix, Inc.: Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update | - Q2 2026 Consolidated Revenue of $101.9 million - - Q2 2026 Net Income of $26.0 million; Adjusted EBITDA of $58.7 million - - Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance... ► Artikel lesen | |
| MINERVA NEUROSCIENCES | 3,624 | +1,00 % | Minerva Neurosciences, Inc: Minerva Neurosciences to Participate in Two Upcoming Investor Conferences | BURLINGTON, Mass., Aug. 28, 2026 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous... ► Artikel lesen | |
| REPLIMUNE | 10,925 | -2,06 % | Replimune Group, Inc.: Replimune Reports Fiscal First Quarter 2027 Financial Results and Provides Corporate Update | TUDRIQEV in combination with nivolumab receives FDA accelerated approval and will launch within 60 days Michelle DiNapoli appointed as Chief Commercial Officer Recently completed financing extends... ► Artikel lesen | |
| VALERIO THERAPEUTICS | 0,686 | 0,00 % | Valerio Therapeutics Announces Signing of Definitive Agreements for the Acquisition of Etherna Immunotherapies, Building a Leading Platform in Targeted RNA, and €40.25 Million PIPE Financing From New and Existing Investors | Definitive share purchase agreement signed for the acquisition of 100% of Etherna Immunotherapies NV ("Etherna"), and the related contribution agreement, based on an enterprise value of €30 million... ► Artikel lesen | |
| RANI THERAPEUTICS | 0,843 | 0,00 % | Rani Therapeutics Announces Positive Initial Phase 1a Data for RT-114 for the Treatment of Obesity, with Oral Bioavailability Exceeding Matched Subcutaneous Dosing | RT-114 achieved systemic exposure greater than 150% relative to a matched 12mg subcutaneous dose of PG-102No adverse events attributed to RaniPill Capsule; treatment-related adverse events were mild... ► Artikel lesen | |
| IO BIOTECH | 0,048 | 0,00 % | NSE - IO Biotech, Inc. - 25, Notification of the removal from listing and registration of matured, redeemed or retired securities | ||
| ALTO NEUROSCIENCE | 32,030 | 0,00 % | Biotech Stocks At 52-Week Highs - Delcath Systems +22% On Q2 Results, Alto Neuroscience, Hemab Therapeutics, Monopar Therapeutics, Nurix Therapeutics | SOUTH SAN FRANCISCO (dpa-AFX) - The following biotech stocks reached 52-week highs on August 7, 2026, driven by key catalysts such as positive quarterly reports or upcoming conference participation.... ► Artikel lesen | |
| CERO THERAPEUTICS | 0,095 | +0,11 % | SRX Global Inc: SRX Global Acquires Senior Secured Debt in CERo Therapeutics Holdings, Inc., an Innovative Cellular Immunotherapy Company with Cancer Fighting Molecule for the Treatment of Hematologic Cancers | NORTH PALM BEACH, Fla., Aug. 31, 2026 (GLOBE NEWSWIRE) -- SRX Global Inc. (NYSE American: SRXH) (the "Company" or "SRX"), an AI-enabled platform dedicated to generating long-term shareholder value... ► Artikel lesen | |
| SUMMIT THERAPEUTICS | 17,550 | 0,00 % | Mercks 30-Milliarden-Dollar-Blockbuster bekommt neue Konkurrenz - warum Big Pharma schon die nächste Plattform sucht | ||
| TANGO THERAPEUTICS | 23,780 | 0,00 % | Tango Therapeutics, Inc.: Tango Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Highlights | Company continues to prepare for late-stage clinical advancement of vopimetostat in combination with daraxonrasib for pancreatic cancer following positive Phase 1/2 data Phase 1/2 data from combination... ► Artikel lesen | |
| RELAY THERAPEUTICS | 18,870 | 0,00 % | Relay Therapeutics: Zovegalisib-Pipeline steht vor entscheidenden Meilensteinen |
OSR HEALTH INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,003 (-2,75 %) liegt der Kurs bei 0,113 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu OSR HEALTH INC finden Sie auf Wallstreet Online.